Group revenue rose 12.7% year-over-year, driven by strong growth in Life Molecular Imaging and solid performance in Southern Africa. ZAR 10.6 billion was returned to shareholders, and a robust balance sheet supports ongoing expansion and efficiency initiatives.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.